ABCL in the 13F filings
Abcellera Biologics Inc · CUSIP 00288U106
- Quarter end
- 30 Jun 2026
- the date the book describes
- Filed
- 2 Sep 2026
- latest of these filings; the earliest 3 Aug 2026
- Managers listing it
- 22
- at least, of 95 tracked, among listed positions
- Comparable managers
- 91
- filed both Q1 2026 and Q2 2026; 1 listed it in both
- Shares listed
- 34,955,749
- combined, among listed positions
- Reported value
- $274m
- combined, at the quarter end
Among the 91 comparable managers: 12 buyers (opened or added shares) and 13 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was +435,759.
Managers listing ABCL in Q2 2026
22 of 22 holders
Largest increases and reductions, by shares
Increases
- T. Rowe Price Associates Incnew position · 1,587,870 shares now+1,587,870
- Marshall Wace LLPexisting position · 1,902,191 shares now+1,542,508
- Arrowstreet Capital LPnew position · 1,039,927 shares now+1,039,927
- Man Group PLCnew position · 228,979 shares now+228,979
- Capital World Investorsexisting position · 13,588,349 shares now+227,253
Reductions
- Millennium Management LLCexisting position · 518,571 shares now-776,003
- Susquehanna International Group LLPexisting position · 20,580 shares now-729,813
- Jane Street Group LLCexisting position · 195,262 shares now-652,621
- Voloridge Investment Management LLCexisting position · 71,345 shares now-539,078
- Renaissance Technologies LLCexisting position · 990,929 shares now-519,700
New positions and exits
New (7)
Exited (3)
- Point72 Asset Management LPwas $4.0m
- Schonfeld Strategic Advisors LLCwas $493k
- Squarepoint Ops LLCwas $111k
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q4 2020 | 4 | $960m | n.a. | n.a. |
| Q1 2021 | 4 | $837m | n.a. | n.a. |
| Q2 2021 | 3 | $364m | n.a. | n.a. |
| Q3 2021 | 3 | $470m | n.a. | n.a. |
| Q4 2021 | 3 | $376m | n.a. | n.a. |
| Q1 2022 | 3 | $287m | n.a. | n.a. |
| Q2 2022 | 5 | $326m | n.a. | n.a. |
| Q3 2022 | 7 | $270m | n.a. | n.a. |
| Q4 2022 | 3 | $294m | n.a. | n.a. |
| Q1 2023 | 4 | $221m | n.a. | n.a. |
| Q2 2023 | 4 | $226m | n.a. | n.a. |
| Q3 2023 | 3 | $160m | n.a. | n.a. |
| Q4 2023 | 3 | $186m | 1 | 2 |
| Q1 2024 | 3 | $144m | 1 | 1 |
| Q2 2024 | 3 | $81m | 0 | 3 |
| Q3 2024 | 1 | $34m | 0 | 2 |
| Q4 2024 | 2 | $59m | 1 | 1 |
| Q1 2025 | 2 | $55m | 1 | 1 |
| Q2 2025 | 3 | $95m | 1 | 1 |
| Q3 2025 | 5 | $147m | 4 | 0 |
| Q4 2025 | 3 | $63m | 15 | 9 |
| Q1 2026 | 1 | $47m | 9 | 12 |
| Q2 2026 | 2 | $189m | 12 | 13 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
ABCL and LLY →ABCL and JNJ →ABCL and VRTX →Choose a stock to compare with ABCL →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own ABCL, latest filings →Back to the 13F Explorer →